Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.79
27.01.21
-
27.01.22
6.17%
28.07.21

Mori8 
27.01.21 50%
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€173.98
25.01.21
€250.00
25.01.22
23.00%
17.01.22

Top 10 in its market
Could be worthwhile Investment >10% per year
High dividend yield expected
Innovative
gerihouse 
25.01.21 90%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€463.95
25.01.21
€500.00
25.01.22
15.42%
26.01.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
WatchMen 
25.01.21 0%
buy
Intuitive Surgical Inc

Start price
Target price
Perf. (%)
€219.23
21.01.21
€215.00
2.46%
15.02.21

Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Traumtanz 
21.01.21 50%
buy
Johnson & Johnson

Start price
Target price
Perf. (%)
€134.68
20.01.21
€144.00
0.89%
02.02.21

Future proof or reliable business model
Could be worthwhile Investment >10% per year
Fair valuation
Innovative
Gilbert 
20.01.21 60%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.31
19.01.21
€67.00
19.01.22
14.53%
20.01.22

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Snowman 
19.01.21 50%
buy
Medtronic plc

Start price
Target price
Perf. (%)
€97.71
10.01.21
-
10.01.22
-2.05%
11.01.22

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Known brand
Maxfloh 
10.01.21 20%
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.89
09.01.21
€68.00
09.01.22
8.15%
30.10.21

Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
RudolfL 
09.01.21 60%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.93
05.01.21
-
05.01.22
10.78%
03.06.21

Could be worthwhile Investment >10% per year
Capable Management
Innovative
Market Leader or Top 3
Trip 
05.01.21 50%
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€60.00
31.12.20
€78.00
31.12.21
10.17%
01.01.22

Could be worthwhile Investment >10% per year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
stepdown 
31.12.20 80%
sell
Incyte Corp.

Start price
Target price
Perf. (%)
€72.06
20.12.20
-
20.12.21
-7.02%
21.02.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Dependend from some customers or products
SpringheelJack 
20.12.20 50%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.01
18.12.20
€45.00
-1.78%
23.12.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Traumtanz 
18.12.20 50%
sell
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€48.17
18.12.20
€27.00
18.06.21
14.83%
19.01.21

Top 10 in its market
Good rating
Medium risks for its business
Bad culture
Snowman 
18.12.20 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.01
18.12.20
€34.00
18.12.21
-5.35%
15.03.21

Small challenges to pay loans and raise capital
Innovative
Very small cyclical dependencies
Some uniques
Snowman 
18.12.20 80%
sell
Pfizer Inc.

Start price
Target price
Perf. (%)
€30.91
17.12.20
€29.00
-1.81%
21.12.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
Traumtanz 
17.12.20 50%
buy
Alexion Pharmaceutical Inc.

Start price
Target price
Perf. (%)
€142.00
13.12.20
€170.00
13.12.21
9.00%
14.12.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
skatcup 
13.12.20 100%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€395.05
12.12.20
-
12.12.21
4.78%
09.01.21

Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Traumtanz 
12.12.20 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€35.01
12.12.20
-
12.12.21
-14.23%
24.03.21

Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
FXX 
12.12.20 50%
sell
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€392.75
11.12.20
€250.00
0.97%
11.12.20

Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Traumtanz 
11.12.20 50%
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.50
30.11.20
€38.00
30.11.21
18.40%
02.08.21

Could be worthwhile Investment >10% per year
Very high dividend yield expected
Fair valuation
Higher EBIT margin than peer group
cbetz100 
30.11.20 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€442.80
23.11.20
€555.00
23.11.21
29.97%
24.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
geldnutzer 
23.11.20 80%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€485.05
23.11.20
€770.00
07.07.23
39.47%
25.05.23

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
ROE higher than 15% per year
RudolfL 
23.11.20 60%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€529.00
22.11.20
€450.00
-25.76%
11.12.20

Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
Traumtanz 
22.11.20 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€529.00
22.11.20
€500.00
22.11.21
7.75%
23.11.21

marge 
22.11.20 50%
buy
Teleflex Inc.

Start price
Target price
Perf. (%)
€308.00
20.11.20
-
20.11.21
8.44%
14.02.21

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
CrazyEights 
20.11.20 50%